DORA-22 NEW
| Price | $133 | $198 | $298 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: DORA-22 | CAS No.: 1088991-95-0 |
| Purity: 97.67% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | DORA-22 |
| Description | DORA-22 is a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory |
| Animal Research | Animals were first trained to remember the location of a hidden platform (acquisition) in the Morris Water Maze and then administered DORA-22 (10, 30, or 100 mg/kg doses) or vehicle control.?Animals were then subjected to a rodent insomnia model involving two exposures to dirty cages over a 6-hr time period (at time points 0 and 3 hr), followed immediately by a probe trial in which memory of the water maze platform location was evaluated[1]. |
| In vivo | DORA-22, a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory.DORA-22 treatment improved the insomnia-related sleep disruption-wake was attenuated and NREM sleep was normalized.?REM sleep amounts were enhanced compared with vehicle treatment for one dose (30 mg/kg).?In the first hour of insomnia model exposure, DORA-22 promoted the number and average duration of NREM sleep spindles, which have been previously proposed to play a role in memory consolidation (all doses).?Water maze measures revealed probe trial performance improvement for select doses of DORA-22, including increased time spent in the platform quadrant (10 and 30 mg/kg) and time spent in platform location and number of platform crossings (10 mg/kg only).?In conclusion, DORA-22 treatment improved insomnia-related sleep disruption and memory consolidation deficits[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (23.56 mM) |
| Keywords | DORA-22 | DORA 22 | DORA22 |
| Inhibitors Related | L-368,899 hydrochloride | YNT-185 | Orexin 2 Receptor Agonist | IPSU | MK-3697 | Filorexant | Orexin B, rat, mouse Acetate | OXA (17-33) acetate | PF3274167 | ACT-462206 | Seltorexant | TCS 1102 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3100.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $10.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-05-17 | |
| $504.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY